Multiple cycles of rituximab therapy in chronic refractory immune thrombocytopenia

A case report with a 10-year follow-up

Bertrand Routy, Mohamed Rachid Boulassel, Gwendoline M. Spurll, Margaret N. Warner, Jean Pierre Routy

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Immune thrombocytopenia (ITP) is an autoimmune disease characterized by isolated low platelet counts often leading to mucocutaneous bleeding. Administration of rituximab was shown to increase platelet counts in patients relapsing chronic ITP. However, duration of response with rituximab and the long-term benefit remains unknown. Herein, the authors presented a case of a 36-year-old splenectomised man with a relapsing ITP who received a total of 10 cycles of rituximab over the last decade with the concomitant assessments of circulating B cells. The data show that rituximab can be an effective therapy over 10 years, and monitoring B cells may help to herald ITP recurrence.

Original languageEnglish
Pages (from-to)219-222
Number of pages4
JournalAmerican Journal of Therapeutics
Volume20
Issue number2
DOIs
Publication statusPublished - Mar 2013

Fingerprint

Idiopathic Thrombocytopenic Purpura
Platelet Count
B-Lymphocytes
Therapeutics
Autoimmune Diseases
Hemorrhage
Recurrence
Rituximab

Keywords

  • B cells
  • Immune thrombocytopenia
  • Platelets
  • Rituximab

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Multiple cycles of rituximab therapy in chronic refractory immune thrombocytopenia : A case report with a 10-year follow-up. / Routy, Bertrand; Boulassel, Mohamed Rachid; Spurll, Gwendoline M.; Warner, Margaret N.; Routy, Jean Pierre.

In: American Journal of Therapeutics, Vol. 20, No. 2, 03.2013, p. 219-222.

Research output: Contribution to journalArticle

Routy, Bertrand ; Boulassel, Mohamed Rachid ; Spurll, Gwendoline M. ; Warner, Margaret N. ; Routy, Jean Pierre. / Multiple cycles of rituximab therapy in chronic refractory immune thrombocytopenia : A case report with a 10-year follow-up. In: American Journal of Therapeutics. 2013 ; Vol. 20, No. 2. pp. 219-222.
@article{e19f8ce5af3a49f4ac23745df570a966,
title = "Multiple cycles of rituximab therapy in chronic refractory immune thrombocytopenia: A case report with a 10-year follow-up",
abstract = "Immune thrombocytopenia (ITP) is an autoimmune disease characterized by isolated low platelet counts often leading to mucocutaneous bleeding. Administration of rituximab was shown to increase platelet counts in patients relapsing chronic ITP. However, duration of response with rituximab and the long-term benefit remains unknown. Herein, the authors presented a case of a 36-year-old splenectomised man with a relapsing ITP who received a total of 10 cycles of rituximab over the last decade with the concomitant assessments of circulating B cells. The data show that rituximab can be an effective therapy over 10 years, and monitoring B cells may help to herald ITP recurrence.",
keywords = "B cells, Immune thrombocytopenia, Platelets, Rituximab",
author = "Bertrand Routy and Boulassel, {Mohamed Rachid} and Spurll, {Gwendoline M.} and Warner, {Margaret N.} and Routy, {Jean Pierre}",
year = "2013",
month = "3",
doi = "10.1097/MJT.0b013e318258905e",
language = "English",
volume = "20",
pages = "219--222",
journal = "American Journal of Therapeutics",
issn = "1075-2765",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Multiple cycles of rituximab therapy in chronic refractory immune thrombocytopenia

T2 - A case report with a 10-year follow-up

AU - Routy, Bertrand

AU - Boulassel, Mohamed Rachid

AU - Spurll, Gwendoline M.

AU - Warner, Margaret N.

AU - Routy, Jean Pierre

PY - 2013/3

Y1 - 2013/3

N2 - Immune thrombocytopenia (ITP) is an autoimmune disease characterized by isolated low platelet counts often leading to mucocutaneous bleeding. Administration of rituximab was shown to increase platelet counts in patients relapsing chronic ITP. However, duration of response with rituximab and the long-term benefit remains unknown. Herein, the authors presented a case of a 36-year-old splenectomised man with a relapsing ITP who received a total of 10 cycles of rituximab over the last decade with the concomitant assessments of circulating B cells. The data show that rituximab can be an effective therapy over 10 years, and monitoring B cells may help to herald ITP recurrence.

AB - Immune thrombocytopenia (ITP) is an autoimmune disease characterized by isolated low platelet counts often leading to mucocutaneous bleeding. Administration of rituximab was shown to increase platelet counts in patients relapsing chronic ITP. However, duration of response with rituximab and the long-term benefit remains unknown. Herein, the authors presented a case of a 36-year-old splenectomised man with a relapsing ITP who received a total of 10 cycles of rituximab over the last decade with the concomitant assessments of circulating B cells. The data show that rituximab can be an effective therapy over 10 years, and monitoring B cells may help to herald ITP recurrence.

KW - B cells

KW - Immune thrombocytopenia

KW - Platelets

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=84875194598&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875194598&partnerID=8YFLogxK

U2 - 10.1097/MJT.0b013e318258905e

DO - 10.1097/MJT.0b013e318258905e

M3 - Article

VL - 20

SP - 219

EP - 222

JO - American Journal of Therapeutics

JF - American Journal of Therapeutics

SN - 1075-2765

IS - 2

ER -